|Day Low/High||49.79 / 51.53|
|52 Wk Low/High||39.07 / 65.51|
- PTC in-licenses regional rights to TEGSEDI™ and WAYLIVRA™ from Akcea -
Investors in Ionis Pharmaceuticals Inc saw new options become available this week, for the September 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IONS options chain for the new September 21st contracts and identified one put and one call contract of particular interest.
Webcast scheduled for Tuesday, August 7th at 11:30 a.m. Eastern Time
-TEGSEDI treatment demonstrated substantial improvement in measures of neuropathy progression and quality of life-
CARLSBAD, Calif., June 18, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.
CARLSBAD, Calif., June 5, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.
In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Ionis Pharmaceuticals Inc was identified as having a larger market cap than the smaller end of the S&P 500, for example Leggett & Platt, Inc. , according to The Online Investor.
Jim Cramer makes the calls on Alibaba, First American, Coherent, Ionis Pharmacuetical, Skechers USA, Corning, Bank of Internet and more.
Love the banks, then hate the banks. Love the industrials? Nope, they're out, too. Jim Cramer says it's ugly, but he would use the weakness in the upside surprises.
First drug to demonstrate lowering of mutant huntingtin, the disease-causing protein, in people with Huntington's disease
Webcast scheduled for Friday, May 4 at 11:30 a.m. Eastern Time
Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals (Nasdaq: IONS) announced today they have expanded their strategic collaboration through a new ten-year collaboration agreement to develop novel antisense drug candidates for a broad range of neurological...
Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.
Continued benefit with long-term inotersen treatment observed in both quality of life (Norfolk-QOL-DN) and neuropathy (mNIS+7) measures in hATTR amyloidosis patients;
Ionis licenses to Akcea worldwide rights to inotersen and IONIS-TTR-L Rx
Biogen (Nasdaq: BIIB) today announced new interim Phase 2 results from NURTURE, the ongoing open-label, single-arm study evaluating the efficacy and safety of SPINRAZA ® (nusinersen) among pre-symptomatic...
Phase 1/2 study first to demonstrate disease-modifying potential
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: EOG, FGEN, GASS, GHC, SATS Downgrades: ALB, CFBK, CLI, DISCB, FORM, HCCI, IONS, KOP, LTC, MNRO, PNTR, SRE Initiations: FRAC, JELD, REVG Read on to get TheStreet Quant Ratings' detailed report:
Ionis earns $30 million license fee
Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc.
Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that they have entered into a new collaboration agreement to identify new antisense oligonucleotide drug candidates for the treatment of...
Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that the end of study results from ENDEAR, the Phase 3 study of SPINRAZA ® (nusinersen) for the treatment of spinal muscular atrophy...
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Ionis Pharmaceuticals Inc , where a total of 10,049 contracts have traded so far, representing approximately 1.0 million underlying shares. That amounts to about 75.1% of IONS's average daily trading volume over the past month of 1.3 million shares.
Biogen (NASDAQ: BIIB) presented new data demonstrating that earlier initiation of treatment with SPINRAZA ® (nusinersen) may improve motor function outcomes in infants and children with spinal muscular atrophy...
Jim Cramer says the market may be shaking off bad news and threats, but recent positivity is unusual. Don't speculate, be diversified and don't feel bad about taking profits.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.